

MarketVue®

Geographic Atrophy (GA)

July 2023



MarketVue®: Geographic Atrophy

UNDERSTAND THE GEOGRAPHIC ATROPHY MARKET

MarketVue market landscape reports combine primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Methodology: Research is supported by 4 qualitative interviews with key opinion leaders (U.S. Ophthalmologists), a quantitative survey with 25 U.S. physicians and secondary research.

Geographies covered: United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

TOPICS COVERED

EPIDEMIOLOGY: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

CURRENT TREATMENT: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

UNMET NEEDS: Identify opportunities to address treatment or disease management gaps

PIPELINE ANALYSIS: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

VALUE AND ACCESS: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



MarketVue®: Geographic Atrophy

UNDERSTAND THE GEOGRAPHIC ATROPHY MARKET

COMPANIES MENTIONED

- Apellis Pharmaceuticals
- Astellas Pharma
- Iveric Bio
- Novartis Pharmaceuticals
- Alexion
- Alkeus Pharmaceuticals
- Belite Bio
- ONL Therapeutics
- Genentech
- Ionis Pharmaceuticals
- Evergreen Therapeutics
- Janssen Research & Development
- Aviceda Therapeutics
- Perceive Biotherapeutics
- Cognition Therapeutics

DRUGS MENTIONED

- Pegcetacoplan (Syfovre)
- AREDS/AREDS2
- Avacincaptad pegol (Zimura)
- Iptacopan
- Danicopan
- ALK-001
- LBS-008 / Tinalirebant
- ONL1204
- GT005
- IONIS-FB-LRx
- ASP7317
- EG-301
- JNJ-81201887
- AVD-104
- VOY-101
- CT1812
- Opregen

MarketVue®: Geographic Atrophy

Table of Contents

1. DISEASE OVERVIEW	5 - 6
A progressive macular degeneration of the retina characterized by irreversible central vision loss	5
Figure 1.1. Risk factors for GA	5
Figure 1.2. Physician-reported proportion of their AMD patients that progress to GA	5
Disease mechanism	6
Figure 1.3. Overactivation of the complement cascade in GA leads to retinal degeneration	6
2. EPIDEMIOLOGY & PATIENT POPULATIONS	7
Disease definition	7
Figure 2.1. U.S. and EU5 diagnosed prevalent cases of GA by region	7
Table 2.1. Prevalent cases of GA in populations aged 50-85 years in the U.S. and EU5	7
3. DIAGNOSIS & CURRENT TREATMENT	8 - 16
Overview	8
Figure 3.1. Referral and treatment pathway for GA	8
Physician insights on diagnosis of GA	9
Before Syfovre, physicians had no treatment options besides convincing patients to enroll in clinical trials	10
Figure 3.2. Current treatment patient share	10
Figure 3.3. Evolving treatment goals for GA, pre- and post-Syfovre approval	10
Syfovre approval is viewed as a first step in GA management; physicians find efficacy underwhelming	11
Figure 3.4. Physician-reported experience/impression of Syfovre	11
Overview of Syfovre's OAKS and DERBY trial data	12
Syfovre demonstrates increasing effects over time with accelerated treatment effect between 18-24 months	13
Table 3.1. Lesion growth reduction was similar in pts with extrafoveal & subfoveal lesions at 18-24 mos	13
Table 3.2. Key insights from OAKS and DERBY trials	13
Ophthalmologists' perspectives on Syfovre	14
Physicians report that there are few but significant barriers to Syfovre uptake	15
Figure 3.5. Ophthalmologist-reported most impactful barriers to receiving treatment with Syfovre	15

MarketVue®: Geographic Atrophy

Table of Contents

Figure 3.6. Percentage of non-prescribers citing reasons for not yet prescribing Syfovre	15
Key treatment dynamics that will shape disease management and drug use in GA	16
Figure 3.7. Important dynamics of GA market evolution	16
4. UNMET NEED	17 - 18
Overview	17
Figure 4.1. Ophthalmologist-reported unmet needs in GA patients	17
Physicians emphasize on the need for txs that not only slow down lesion growth but also provide functional benefit	18
5. PIPELINE ANALYSIS	19 - 25
Overview	19
Figure 5.1. Number of emerging therapies in Ph 3 and Ph 2 addressing key unmet needs in GA	19
Figure 5.2. Ophthalmologist-reported most promising mechanisms of action in the pipeline	19
GA pipeline is active with several therapies in Ph 2 and 3 development	20
Table 5.1. Key Phase 3 trials of drugs in development for GA	20
Complement inhibitors and cell/gene therapies dominate the mid-late stage GA pipeline	21
Table 5.2. Ongoing key Phase 2 trials of therapies in development for GA	21
Complement inhibitors and cell/gene therapies appear to be the future of GA management	22
Table 5.2. (contd.) Ongoing key Phase 2 trials of therapies in development for GA	22
Astellas Pharmaceutical's Zimura is poised to compete for GA patient share, if approved	23
Figure 5.3. Select results from Phase 3 trials of Zimura in GA patients	23
There have been several failures of complement-targeted therapies in clinical development for GA	24
Table 5.3. Clinical trial failures of complement-targeted therapies	24
Figure 5.4. Physician-reported most meaningful trial outcomes to assess functional benefit	24
Physician perspectives on patient selection and outcomes in clinical trials	25
6. VALUE AND ACCESS	26 - 27
Overview	26
Table 6.1. Current pricing of select GA treatments	26

MarketVue®: Geographic Atrophy

Table of Contents

Table 6.2. Typical U.S. commercial payer coverage of Syfovre	26
Syfovre access and reimbursement dynamics in GA	27
Figure 6.1. GA patients by insurance type, U.S.	27
Figure 6.2. Figure 6.2. Reimbursement and Access Considerations for Emerging Therapies in GA	27
Figure 6.3. Ophthalmologist-reported percentage of patients who have difficulty accessing and/or staying on Syfovre due to insurance restrictions, high OOP costs, or prior authorizations	27
7. METHODOLOGY	28 - 29
Primary market research approach	28
Epidemiology methodology	29
Disease definition	29
Diagnosed prevalence estimates	29

Meet the REACH Team



DANIELLE DRAYTON, PhD., Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



MELISSA CURRAN is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



MICHAEL HUGHES, MSc, Ph.D., Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

Meet the REACH Team



TYLER JAKAB, MPH is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



BAYLEY KOOPMAN is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



BRIANA MULLINS is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.